Vivacare Partners with Asthma and Allergy Network

Digital health and patient education company Vivacare is announcing today their partnership with Asthma and Allergy Network to provide a digital patient education service to their 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers.
AAN members who enroll for the service receive a personalized “Patient Education Toolkit” pre-loaded with in-depth disease education resources, including printable handouts, videos, and patient support tools that can be easily distributed to patients via print, email, text or displayed on the provider’s own website. The service makes it easy for health care providers to deliver doctor-recommended health information to their patients to help them prepare for their appointments and manage their condition from home.
AAN members will receive patient education resources from Allergy and Asthma Network, including a range of titles covering asthma, eczema and other allergic conditions. Eczema-focused titles include “Eczema – What Is It?”, “Moisturizers for Eczema” “Biologics for Eczema”, “Eczema Skin Care” and more. Asthma-related titles include “Understanding Asthma”, “Asthma Action Plan” and “Asthma Treatment & Medications”. The unbranded disease awareness and education content is made possible through the generous support provided by Sanofi and Regeneron.
The patient education service also enables physicians to share their own clinical expertise with patients by publishing their own patient handouts or “Tips & Wisdom” – quick thoughts on clinical issues of importance to patients. In October, for Eczema Awareness Month, Vivacare is inviting enrolled physicians to publish their Tips regarding Eczema. For example, Pediatric dermatologist Jeffrey Poole has provided his Tips on the use of bleach baths to reduce eczema flares, Ohio dermatologist Dr. Eliot Mostow published his step-wise approach to treating atopic dermatitis and Dr. Eliot Ghatan of New York City shared his skin care tips for those with eczema.
Dr. Mark Becker, Pediatrician, Founder and CEO of Vivacare says, “Vivacare wants to make it easy for physicians to share their expertise with patients. After years of medical practice, clinicians have gained unique insights that can help their patients better manage their care and we encourage them to publish their pearls of wisdom. In regards to eczema, dermatologists have a wealth of knowledge to share with their patients about what to expect, how to manage it and how to evaluate treatment options.”
These resources are delivered through a doctor-branded channel so patients receive information from the source they trust most, their own provider.
SourceVivacare

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version